Big investors are conservative and come from the “Show Me” line of thinking. The only thing they care about is a solid answer to “how much and when?” That solid answer only comes when Flaskworks is validated, fitted out at Sawston and producing at the rate expected. Then the big wallets open. Other investors will be able to trade on other risk off opportunities sooner which is what will drive later offers up to legit levels. Best wishes.
Don’t point fingers at management otherwise you will be called names . Whatever you pointed are foreign concepts to the usual few here . Playing victim card all the time is the best strategy .
How could you know big investors haven't valued the company? IMO, they value a lot. The simple fact is that you can sense it.
Let me ask you a simple question? Do you think Teresa Bitetti, President, Global Oncology Business Unit at Takeda knew about DCVax-L? Of course, she knew. BMS must do some DDs before striking a collaboration trial deal with NWBO which was taken away by Merck later. Is it coincident that Takeda has the aspiration to cure cancer after Teresa Bitetti joined the company? There is no coincidence in biotech.
The trial SAP is sui generis, you know that. It's not crazy to think that conservative investors might not want to jump in before seeing the MHRA approved. I'm not saying we have any proof this should be a show-stopping issue, just that it credibly might be.
Investor, the years of 'silent mode' now followed at the asm with 'stealth mode' has not served long time Investors very well. They do give some presentations touting what they have but it is done by LG on the big biz show. One has to ask if this is the best strategy. As I see it nwbo trades near a 52 week low while the major averages at all time highs. Perhaps time to tell the success story in a different venue